Sanjiv S. Agarwala, MD: Dirk, talking about the BRAF-positive population, the COLUMBUS trial was updated, you know, with the most recent BRAF/MEK combo.
Video Reports
Dr. Polsky on the Predictive Value of ctDNA in BRAF-Mutant Melanoma
David Polsky, MD, PhD, Alfred W. Kopf, MD Professor of Dermatologic Oncology, Ronald O. Perelman Department of Dermatology, professor, Department of Pathology, and director, Pigmented Lesion Service, NYU Langone’s Perlmutter Cancer Center, discusses the predictive value of circulating tumor DNA (ctDNA) in BRAF-mutant melanoma.
Melanoma Progression Following Adjuvant Therapy
Sanjiv S. Agarwala, MD: Before we end adjuvant therapy, though, I have 1 quick question. People are getting adjuvant therapy now.
Intralesional Therapy for Metastatic Melanoma
Jeffrey S. Weber, MD, PhD: Let’s go to the other end of the spectrum for a moment and turn back to Vern. We’re also going to hear, at this ASCO [American Society of Clinical Oncology Annual Meeting], about the long-term follow-up of the OPTiM study.